The FDA approved Moderna's mFlusiva in August, and it's now available to adults 50 and older.

So the stock is attached to a real, maturing franchise. The question is what the mRNA platform is worth, and the honest ...

Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would ...

Find out how different vaccines for the coronavirus cause your body to create antibodies that fight the virus.

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times ...

Trials investigating mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway.

For some older adults, the flu vaccine could look a little different this year. In August, the U.S. Food and Drug Administration approved the nation's first mRNA-based flu vaccine for use in people 50 ...

PopVax's PVX-001 is designed to remain stable at 2-8°C for at least nine months and protect against a broad range of covid-19 ...

People looking to get their annual flu shot this fall may find a new option alongside the usual vaccines: an mRNA flu shot. Not everyone is eligible, however.

A new review synthesizes preclinical and clinical evidence showing that lipid nanoparticle biodistribution, mRNA persistence, ...

The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu vaccines. On August 5, the US Food and Drug Administration approved ...

The FDA approved Moderna’s mFlusiva, an mRNA seasonal flu vaccine for adults aged 50 and older, marking a major expansion ...